IRWD - アイアンウッド・ファ―マシュ―ティカルズ (Ironwood Pharmaceuticals Inc.) アイアンウッド・ファ―マシュ―ティカルズ

 IRWDのチャート


 IRWDの企業情報

symbol IRWD
会社名 Ironwood Pharmaceuticals Inc (アイアンウッド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイアンウッド・ファーマシューティカルス(Ironwood Pharmaceuticals Inc.)はバイオテクノロジー企業である。同社は便秘過敏性腸症候群(IBS C)、慢性特発性便秘(CIC)、制御不能な痛風に関連する高尿酸血症、制御不能な胃食道逆流症(無制御性GERD)、血管および線維症等の分野の製品を開発する。同社は人体治療事業セグメントを運営する。同社の製品リナクロチドは「LINZESS」という商標名で米国のIBS CまたはCICに罹患している成人男性および女性に可能でき、商標名「CONSTELLA」で特定のヨーロッパ諸国のIBS Cに罹患している成人男性および女性に利用可能である。同社はまた、GERDを有する患者において対症的軽減をもたらす可能性のある胆汁酸封鎖剤の胃保持製剤IW-3718を開発する。血管・線維プログラムには可溶性グアニル酸シクラーゼ(sGC)を標的とするIW-1973およびIW-1701が含まれる。   アイアンウッド・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。消化器・循環器系疾患、疼痛、炎症などの治療薬の発見、開発、商業化に従事。主要製品には、成人の便秘を伴う慢性特発性便秘と過敏性腸症候群の治療薬「リンゼス」(リナクロチド)がある。欧州連合(EU)においての、この治療薬の商標名は「コンステラ」。本社はマサチュ―セッツ州。   Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
本社所在地 301 Binney Street Cambridge MA 02142 USA
代表者氏名 Peter M. Hecht Peter M. Hecht
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +1 617-621-7722
設立年月日 35796
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 730人
url www.ironwoodpharma.com
nasdaq_url https://www.nasdaq.com/symbol/irwd
adr_tso
EBITDA EBITDA(百万ドル) -46.26500
終値(lastsale) 17.89
時価総額(marketcap) 2739986136.46
時価総額 時価総額(百万ドル) 2559.26
売上高 売上高(百万ドル) 331.29400
企業価値(EV) 企業価値(EV)(百万ドル) 2785.16
当期純利益 当期純利益(百万ドル) -112.73600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ironwood Pharmaceuticals Inc. revenues increased 28% to $150.3M. Net loss decreased 4% to $92.5M. Revenues reflect Collaborative arrangements revenue increase of 15% to $134.3M Product revenue net increase from $754K to $1.7M. Lower net loss reflects loss decrease of 71% to $2.5M (expense) Loss on extinguishment of debt decrease from $2M (expense) to $0K.

 IRWDのテクニカル分析


 IRWDのニュース

   Ironwood Pharmaceuticals EPS beats by $0.12, beats on revenue  2021/08/05 11:06:43 Seeking Alpha
   Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance  2021/08/05 11:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported financial results for second quarter 2021 and raised full year 2021 financial guidance. Commenting on the results, Tom McCourt, chief executive officer of Ironwood, said: Continued exceptional execution behind a sound strategy resulted in another outstanding quarter for Ironwood. Building on the momentum of LINZESS and its impressive growth, we remain in a position of strengt
   Ironwood Pharmaceuticals Q2 2021 Earnings Preview  2021/08/04 14:48:42 Seeking Alpha
   Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer  2021/08/03 11:30:00 Wallstreet:Online
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwoods Leadership Team and oversee the companys Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt
   The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs  2021/07/29 12:15:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDAQ: RGEN ) (reacted to second-quarter results) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services, Inc. (NYSE: WST ) Translate Bio, Inc. (NASDAQ: TBIO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) 89bio, Inc. (NASDAQ: ETNB ) Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS ) Adicet Bio, Inc. (NASDAQ: ACET ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Biodesix, Inc. (NASDAQ: BDSX ) Candel Therapeutics, Inc.
   Ironwood Pharmaceuticals gains on takeover speculation after 8-K filing  2021/06/25 14:04:09 Seeking Alpha
   A Look At Ironwood Pharmaceuticals'' (NASDAQ-IRWD) Share Price Returns  2021/06/19 18:00:36 Yahoo Finance
A Look At Ironwood Pharmaceuticals'' (NASDAQ:IRWD) Share Price Returns Yahoo Finance
   Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)  2021/06/16 11:45:00 Wallstreet:Online
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology the official journal of The American College of Gastroenterology published full results from the companys Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome
   Ironwood Pharmaceuticals Announces Leadership Updates Wire  2021/06/14 00:01:17 Business Wire
Ironwood Pharmaceuticals Announces Leadership Updates Business Wire
   Ironwood Pharmaceuticals names Thomas McCourt permanent CEO  2021/06/07 20:06:01 Seeking Alpha
   Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences  2021/02/19 21:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:00 a.m. EST Cowen Annual Health Care Conference on Tuesday, March 2, 2021 at 11:10 a.m. EST Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 3:35 p.m. EST A live webcast of Ironwood’s presentations will be accessible
   Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance  2021/02/17 12:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2020 results and recent business performance. “The fourth quarter marked a strong finish to 2020, which is a testament to the hard work and dedication of the Ironwood team. LINZESS U.S. net sales grew 10% year-over-year in 2020 – remarkable growth in the face of the COVID-19 pandemic – and Ironwood delivered its second full year of
   Ironwood CEO Steps Down Months After Clinical Trial Failure, Names Thomas McCourt As Interim Chief Executive  2021/02/09 04:58:00 Benzinga
Ironwood Pharmaceuticals Inc’s (NASDAQ: IRWD) chief executive officer, Mark Mallon, will step down, effective March 12, “to …
   Ironwood Pharmaceuticals Announces CEO Transition  2021/02/08 21:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Mark Mallon plans to step down as chief executive officer and a member of the Ironwood Board of Directors in order to pursue another leadership opportunity, effective March 12, 2021. The Ironwood Board has named Thomas McCourt, Ironwood’s president, as interim CEO effective upon Mr. Mallon’s departure. Julie McHugh, Ironwood’s Board chair, will become executive chair of
   Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call  2021/02/03 21:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full year 2020 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 17, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 4598414. To access the webcast, please visit the Investors section of Ironwood’s

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイアンウッド・ファ―マシュ―ティカルズ IRWD Ironwood Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)